Literature DB >> 12770993

Successful photodynamic therapy for subretinal neovascularisation due to Sorsby's fundus dystrophy: 1 year follow up.

S C Wong, K C S Fong, N Lee, K Gregory-Evans, C Y Gregory-Evans.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12770993      PMCID： PMC1771690          DOI： 10.1136/bjo.87.6.796

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  10 in total

1.  What is Sorsby's fundus dystrophy?

Authors:  K Gregory-Evans
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

2.  Treatment of juxtafoveal and extrafoveal choroidal neovascularization in the era of photodynamic therapy with verteporfin.

Authors:  Lee M Jampol; Lance Scott
Journal:  Am J Ophthalmol       Date:  2002-07       Impact factor: 5.258

3.  A fundus dystrophy with unusual features.

Authors:  A SORSBY; M E J MASON
Journal:  Br J Ophthalmol       Date:  1949-02       Impact factor: 4.638

4.  Sorsby's fundus dystrophy. A light and electron microscopic study.

Authors:  M R Capon; J Marshall; J I Krafft; R A Alexander; P S Hiscott; A C Bird
Journal:  Ophthalmology       Date:  1989-12       Impact factor: 12.079

5.  Sorsby fundus dystrophy: reevaluation of variable expressivity in patients carrying a TIMP3 founder mutation.

Authors:  U Felbor; C Benkwitz; M L Klein; J Greenberg; C Y Gregory; B H Weber
Journal:  Arch Ophthalmol       Date:  1997-12

6.  Sorsby's fundus dystrophy in the British Isles: demonstration of a striking founder effect by microsatellite-generated haplotypes.

Authors:  S D Wijesuriya; K Evans; M R Jay; C Davison; B H Weber; A C Bird; S S Bhattacharya; C Y Gregory
Journal:  Genome Res       Date:  1996-02       Impact factor: 9.043

7.  Night blindness in Sorsby's fundus dystrophy reversed by vitamin A.

Authors:  S G Jacobson; A V Cideciyan; G Regunath; F J Rodriguez; K Vandenburgh; V C Sheffield; E M Stone
Journal:  Nat Genet       Date:  1995-09       Impact factor: 38.330

Review 8.  Senile macular degeneration: review of epidemiologic features.

Authors:  F L Ferris
Journal:  Am J Epidemiol       Date:  1983-08       Impact factor: 4.897

9.  Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5.

Authors:  Mark S Blumenkranz; Neil M Bressler; Susan B Bressler; Guy Donati; Gary Edd Fish; Laurie A Haynes; Hilel Lewis; Joan W Miller; Jordi M Monés; Michael J Potter; Constantin Pournaras; Al Reaves; Philip J Rosenfeld; Andrew P Schachat; Ursula Schmidt-Erfurth; Michel Sickenburg; Lawrence J Singerman; Jason S Slakter; Andrew Strong; Stéphane Vannier
Journal:  Arch Ophthalmol       Date:  2002-10

10.  Recurrent choroidal neovascularization after laser photocoagulation in Sorsby's fundus dystrophy.

Authors:  F G Holz; R Haimovici; D G Wagner; A C Bird
Journal:  Retina       Date:  1994       Impact factor: 4.256
  10 in total
  4 in total

1.  Decreased thickness and integrity of the macular elastic layer of Bruch's membrane correspond to the distribution of lesions associated with age-related macular degeneration.

Authors:  N H Victor Chong; Jason Keonin; Phil J Luthert; Christina I Frennesson; David M Weingeist; Rachel L Wolf; Robert F Mullins; Gregory S Hageman
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

2.  Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization due to Sorsby macular dystrophy.

Authors:  Kapil G Kapoor; Sophie J Bakri
Journal:  J Ocul Pharmacol Ther       Date:  2013-04-12       Impact factor: 2.671

Review 3.  Sorsby fundus dystrophy (SFD): A narrative review.

Authors:  Georgios Tsokolas
Journal:  Medicine (Baltimore)       Date:  2022-09-23       Impact factor: 1.817

Review 4.  Visual Outcome after Intravitreal Anti-VEGF Therapy for Macular Neovascularisation Secondary to Sorsby's Fundus Dystrophy: A Systematic Review.

Authors:  Arthur Baston; Christin Gerhardt; Souska Zandi; Justus G Garweg
Journal:  J Clin Med       Date:  2021-05-30       Impact factor: 4.241
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.